Colorectal cancer (CRC) remains one of the leading causes of cancer-related mortality
worldwide. Its complexity is influenced by various signal transduction networks that govern …

In the past decade, chimeric antigen receptor (CAR)-T cell therapy has emerged as a
promising immunotherapeutic approach for combating cancers, demonstrating remarkable …

Abstract Chimeric Antigen Receptor (CAR) T cell immunotherapy is revolutionizing treatment
for patients suffering from B‐cell lymphoma (BL). However, the current method of CAR T cell …

Chimeric antigen receptor T cell denoted as CAR-T therapy has realized incredible
therapeutic advancements for B cell malignancy treatment. However, its therapeutic validity …

Abstract Antibody-mediated rejection (AMR), including chronic AMR (cAMR), causes~ 50%
of kidney allograft losses each year. Despite attempts to develop well-tolerated and effective …

This last decade, chimeric antigen receptor (CAR) T-cell therapy has become a real
treatment option for patients with B-cell malignancies, while multiple efforts are being made …

Chimeric antigen receptor macrophage (CAR-MΦ) represents a significant advancement in
immunotherapy, especially for treating solid tumors where traditional CAR-T therapies face …

Cancer immunotherapy harnesses the body's immune system to combat malignancies,
building upon an understanding of tumor immunosurveillance and immune evasion …

The manufacturing of autologous chimaeric antigen receptor (CAR) T cells largely relies
either on fed-batch and manual processes that often lack environmental monitoring and …

Background The FDA's alerts regarding the T-cell lymphoma risk post CAR-T therapy has
garnered global attention, yet a comprehensive profile of second primary malignancies …